|D064726||Triple Negative Breast Neoplasms NIH||0.58|
|D011471||Prostatic Neoplasms NIH||0.45|
There is one clinical trial.
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of MGC018 administered alone and in combination with MGA012 in patients with advanced solid tumors.
Description: Safety is based on evaluation of adverse events (AEs) and serious adverse events (SAEs) from the time of study drug administration through the End of Study visit.Measure: Incidence of Adverse Events of MGC018 and MGC018 + MGA012 as assessed by CTCAE v4.03 Time: 30 days after last dose
Description: Maximum tolerated or maximum administered dose of MGC018 and MGC018 + MGA012Measure: Maximum Tolerated Dose Time: up to 42 days from first dose
Description: Efficacy assessed as best overall response rate using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)Measure: Preliminary anti-tumor activity of MGC018 and MGC018+MGA012 Time: 24 months
Description: Percent of prostate cancer patients with at least 50% reduction in prostate-specific antigen (PSA)Measure: PSA response rate Time: 24 months
Description: For prostate cancer patients, time from first dose to first radiographic progression in soft tissue or bone, or death from any causeMeasure: Radiographic progression-free survival Time: 24 months
Description: For prostate cancer patients, change from baseline in pain intensity as measured by the Brief Pain Inventory-Short Form scaleMeasure: Patient-reported Outcome Time: 24 months
Description: Area under the plasma concentration versus time curve of MGC018 and MGC018+MGA012Measure: Area under the curve Time: 24 months
Description: Maximum Plasma Concentration of MGC018 and MGC018+MGA012Measure: Cmax Time: 24 months
Description: Time to reach maximum (peak) plasma concentration of MGC018 and MGC018+MGA012Measure: Tmax Time: 24 months
Description: Trough plasma concentration of MGC018 and MGC018+MGA012Measure: Ctrough Time: 24 months
Description: Total body clearance of the drug from plasma of MGC018 and MGC018+MGA012Measure: CL Time: 24 months
Description: Apparent volume of distribution at steady state of MGC018 and MGC018+MGA012Measure: Vss Time: 24 months
Description: Terminal half life of MGC018 and MGC018+MGA012Measure: t1/2 Time: 24 months
Description: Percent of patients with anti-drug antibodies against MGC018 and MGA012Measure: Immunogenicity Time: 24 months
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports